Ameliorative effect of vitamin C on chronic chlorpyrifos-induced erythrocyte osmotic fragility in Wistar rats.
Chronic exposure to chlorpyrifos (CPF) has been shown to cause increased lipoperoxidative changes in the erythrocyte membranes. The relationship between chronic CPF-induced lipoperoxidative changes and erythrocyte fragility has not been elucidated. The aim of the present study is to evaluate the role of lipoperoxidation on CPF-induced erythrocyte fragility and the ameliorative effect of vitamin C. Twenty animals divided at random into four groups of five animals each served as subject for this study. Rats in group I served as the control group and were given only soya oil at a dose of 2 mL/kg body weight (b.w.). Rats in group II were dosed with vitamin C (100 mg/kg b.w.) and then supplemented with soya oil (2 mL/kg b.w.), while those in group III were administered with CPF only at a dose of 10.6 mg/kg b.w. (~one-eighth of the previously determined median lethal dose [LD(50)]). Rats in group IV were pretreated with 100 mg/kg b.w. of vitamin C, and then dosed with CPF at a dose of 10.6 mg/kg b.w., 30 min later. The different treatment regimens were orally administered daily for a period of 17 weeks. Blood collected from the animals at the end of the test period were analyzed for erythrocyte osmotic fragility and malonaldehyde (MDA) concentration as an index of lipid peroxidation. The study showed that CPF caused significant increase in erythrocyte fragility and MDA concentration, which were ameliorated by pretreatment with vitamin C. In conclusion, the study showed that CPF-evoked erythrocyte fragility due to increased lipoperoxidative changes was ameliorated by pretreatment with vitamin C.
Ambali
Suleiman F
SF
Department of Veterinary Physiology and Pharmacology, Ahmadu Bello University, Zaria, Nigeria. fambali2001@yahoo.com
Ayo
Joseph O
JO
Ojo
Samuel A
SA
Esievo
King A N
KA
D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use*; D001205:Ascorbic Acid / Q000627:therapeutic use*; D004390:Chlorpyrifos / Q000633:toxicity*; D002800:Cholinesterase Inhibitors / Q000633:toxicity; D004912:Erythrocytes / Q000187:drug effects* / Q000378:metabolism; D007306:Insecticides / Q000633:toxicity*; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D009996:Osmotic Fragility; D018384:Oxidative Stress / Q000187:drug effects*; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D036401:Toxicity Tests, Chronic
D000975:Antioxidants; D002800:Cholinesterase Inhibitors; D007306:Insecticides; D008315:Malondialdehyde; D004390:Chlorpyrifos; D001205:Ascorbic Acid